Copyright © Inderes 2011 - present. All rights reserved.

Biohit

2.29

 

EUR

 

0 %

BIOBV

NASDAQ Helsinki

Medical Equipment & Services

Health Care

4,725 following
0%
-6.15%
+7.51%
+16.24%
+21.49%
+19.9%
+20.53%
-28.44%
-55.96%
investors.biohithealthcare.com/en

Biohit is a medical technology company. The company develops and manufactures laboratory equipment, supplies, and diagnostic analysis systems adapted for research, care, and industrial laboratories. In addition to the main activities, technical support, maintenance, and training services are offered within the mentioned work area. The largest presence is in the Nordic market. The company is headquartered in Helsinki.

P/E (adj.) (24e)
18.11
EV/EBIT (adj.) (24e)
13.93
P/B (24e)
3.01
Dividend yield-% (24e)
-
Target price
2.70 EUR
Recommendation
Accumulate
Updated
8.8.2024
NASDAQ Helsinki
BIOBV
Daily low / high price
2.24 / 2.32 EUR
Market cap
34.77M EUR
Turnover
20.68K EUR
Volume
9.1K
Business risk
Valuation risk
Current
Previous

Latest research

Biohit: Growth measures taking effect
15.02.2024
Biohit: From basics to growth mode
20.12.2023
Biohit: Positive result from H1 test
10.08.2023

Extensive report

Inderes' extensive report is an investor's handbook on customer companies covered by our research.
The latest extensive report was released
Read the report

Analyst

Antti Siltanen
Antti Siltanen
Analyst

Latest videos

Life Science Companies as Investments | Life Science Night Dec. 2, 2024
02.12.2024
Biohit: Preconditions for a turnaround
03.07.2023

Financial calendar

Annual report
12.02.2025
General meeting
04.06.2025
Interim report
06.08.2025

Income statement

20202021202220232024e2025e2026e2027e
Revenue7.19.411.013.115.117.419.822.4
growth-%-29.1 %31.4 %17.0 %19.2 %15.9 %15.3 %13.5 %13.0 %
EBITDA-1.20.51.62.12.42.63.44.0
EBIT (adj.)-3.2-1.51.11.82.02.32.83.3
EBIT-3.2-1.51.11.82.02.32.83.3
Profit before taxes-3.3-1.30.92.22.32.53.03.5
Net income-3.3-1.50.61.81.92.02.42.8
EPS (adj.)-0.22-0.100.040.120.130.130.160.18
growth-%189.9 %9.2 %4.9 %20.9 %14.8 %
Dividend0.000.000.000.000.000.000.030.06
Dividend ratio18.7 %30.0 %

Profitability and return on capital

20202021202220232024e2025e2026e2027e
EBITDA-%-16.5 %5.4 %14.7 %16.1 %16.0 %14.9 %17.3 %18.0 %
EBIT-% (adj.)-44.6 %-15.8 %10.3 %13.4 %13.3 %12.9 %14.3 %14.7 %
EBIT-%-44.6 %-15.8 %10.3 %13.4 %13.3 %12.9 %14.3 %14.7 %
ROE-28.3 %-18.5 %8.0 %20.6 %18.3 %16.0 %16.5 %16.3 %
ROI-25.9 %-17.7 %14.3 %19.1 %19.3 %18.9 %20.6 %20.3 %

Valuation

20202021202220232024e2025e2026e2027e
Share price (EUR)2.481.841.571.922.292.292.292.29
Shares15.015.015.015.115.115.115.115.1
Market cap37.327.723.629.034.634.634.634.6
Enterprise value31.622.318.324.528.025.924.122.2
EV/S4.42.41.71.91.91.51.21.0
EV/EBITDA-44.011.411.711.610.07.05.5
EV/EBIT (adj.)--16.314.013.911.58.56.8
EV/EBIT--16.314.013.911.58.56.8
P/E (adj.)--39.316.618.117.314.312.4
P/E--39.316.618.117.314.312.4
P/B4.23.83.13.13.02.62.21.9
P/S5.23.02.22.22.32.01.71.5
Dividend yield1.3 %2.4 %
Equity ratio81.6 %76.7 %68.7 %73.1 %78.6 %84.3 %84.7 %84.9 %
Gearing ratio-64.7 %-72.4 %-69.8 %-47.6 %-57.3 %-64.1 %-66.1 %-67.8 %

Quarter data

Q3/23Q4/232023Q1/24Q2/24Q3/24eQ4/24e2024eQ1/25e
Revenue6.613.17.47.715.1
EBITDA0.42.11.51.02.4
EBIT0.31.81.30.82.0
Profit before taxes0.52.21.50.92.3
Net income0.51.81.30.71.9
Login in to make your own estimates and see other investors estimates.
ShowingAll content types
Analyst Comment by
Antti Siltanen

Biohit is working on a new market launch and FDA approval

Biohit that reports semi-annually does not publish business reviews for Q1 and Q3, but the company reports on its progress on the IR blog. The Q3 blog did not comment on progress against financial targets this time, so we expect the business to have continued to operate within the guidance range of 15-20% growth.

Biohit

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Biohit H1'24 preview: Opening of a new strategy period
Analyst Comment by
Antti Siltanen

Biohit H1'24 preview: Opening of a new strategy period

Biohit will release its H1 report on Wednesday, August 7 at 9:30 am EEST. We expect the company to continue healthy growth during the first six months of the new strategy period. We expect the result to be at the level of the comparison period, as growth investments increase costs.

Biohit
Analyst Comment by
Antti Siltanen

Biohit strengthens R&D

On Friday, Biohit announced that it will change its organization to strengthen the company’s strategic and operational performance of R&D.

Biohit
Analyst Comment by
Antti Siltanen

Biohit's Q1 has gone according to plan

Biohit that reports semi-annually does not publish business reviews for Q1 and Q3 but the company reports on its progress in the CEO’s blog. According to the blog, the implementation of the new strategy 2024-2028 started in Q1 as planned and on schedule.

Biohit